Pharmaceutical

Boehringer reinforces interest in NASH with new $2bn deal  

This collaboration comes six years after the German company Boehringer signed two agreements to develop treatments for NASH.

Jan 3, 2024 - 18:00
Boehringer reinforces interest in NASH with new $2bn deal  
This collaboration comes six years after the German company Boehringer signed two agreements to develop treatments for NASH.
Read the original article

Tags:

Previous Article

Opinion: Today’s at-home microbiome testing industry is fraught with snake oil

Next Article

Novartis allies with Voyager to develop gene therapies in $1.3bn deal

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Kellogg’s is going to war over Mexico’s nutrition label rules. A similar fight is coming to the U.S.

Kellogg’s is going to war over Mexico’s nutrition label...

Aug 21, 2023

Abera and Orexo partner for vaccine powder formulations

Abera and Orexo partner for vaccine powder formulations

Dec 19, 2024

Otsuka and Lundbeck receive NDA approval from FDA for Abilify Asimtufii

Otsuka and Lundbeck receive NDA approval from FDA for A...

Apr 28, 2023